GSK Glaxosmithkline Total Orphan Drugs

In by Cameron

GSK's treatment for cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA). This is the FDA's 32nd Breakthrough Therapy Designation.